864 related articles for article (PubMed ID: 33937022)
1. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
2. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
3. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
[TBL] [Abstract][Full Text] [Related]
4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
5. IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients.
Zeng J; Zhang J; Yang YZ; Wang F; Jiang H; Chen HD; Wu HY; Sai K; Hu WM
Am J Transl Res; 2020; 12(8):4702-4714. PubMed ID: 32913543
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Prognostic Implications of 1p/19q,
Yang Z; Ling F; Ruan S; Hu J; Tang M; Sun X; Long W
Cancer Manag Res; 2021; 13():8755-8765. PubMed ID: 34849029
[TBL] [Abstract][Full Text] [Related]
7. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
8. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of
Xu X; Zhong Z; Shao Y; Yi Y
Front Genet; 2021; 12():679097. PubMed ID: 34220951
[TBL] [Abstract][Full Text] [Related]
12. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
13. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
14. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
Zhang X; Sun X; Guo C; Li J; Liang G
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
[TBL] [Abstract][Full Text] [Related]
15. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
Li JW; Huang QR; Mo LG
Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
17.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
18. Expression and Prognostic Role of Glia Maturation Factor-γ in Gliomas.
Liu J; Zhu X; Gao L; Geng R; Tao X; Xu H; Chen Z
Front Mol Neurosci; 2022; 15():906762. PubMed ID: 35845613
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of RBBP4 gene in lower-grade glioma: An integrative analysis.
Liang R; Xiang Y; Hu C; Tang X
Biochem Biophys Rep; 2023 Sep; 35():101533. PubMed ID: 37664524
[TBL] [Abstract][Full Text] [Related]
20. Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples.
Rao M; Yang Z; Huang K; Liu W; Chai Y
J Mol Neurosci; 2022 Feb; 72(2):420-432. PubMed ID: 34939148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
